Related Experiment Video
Updated: Jan 26, 2026

Quantifying the Antifungal Activity of Peptides Against Candida albicans
Published on: January 13, 2023
Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida
Haroldo Cesar de Oliveira1,2, Maria Candida Monteiro1, Suélen Andreia Rossi1
1Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Abstract:
Candida auris is an emerging fungal pathogen of great concern among the scientific community because it is causing an increasing number of hospital outbreaks of difficult management worldwide. In addition, isolates from this species frequently present reduced susceptibility to azole and echinocandin drugs. For this reason, it is necessary to develop new antifungal strategies to better control the disease caused by this yeast. In this work, we screened drugs from the Prestwick chemical library, which contains 1,280 off-patent compounds that are already approved by the Food and Drug Administration, with the aim of identifying molecules with antifungal activity against C. auris. In an initial screening, we looked for drugs that inhibited the growth of three different C. auris strains and found 27 of them which it did so. Ten active compounds were selected to test the susceptibility profile by using the EUCAST protocol. Antifungal activity was confirmed for seven drugs with MICs ranging from 0.5 to 64 mg/L. Some of these drugs were also tested in combination with voriconazole and anidulafungin at sub-inhibitory concentrations. Our results suggest synergistic interactions between suloctidil and voriconazole with fractional inhibitory concentration index (FICI) values of 0.11 to 0.5 and between ebselen and anidulafungin (FICI, 0.12 to 0.44). Our findings indicate that drug repurposing could be a viable alternative to managing infections by C. auris.
Insights
Drug repurposing identified new antifungal agents against the challenging pathogen Candida auris. Seven FDA-approved drugs showed activity, with synergistic effects noted for suloctidil and ebselen combinations.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Candida auris is a significant global health threat, causing difficult-to-treat hospital outbreaks.
- C. auris exhibits resistance to common antifungal drugs like azoles and echinocandins, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify existing FDA-approved drugs with antifungal activity against Candida auris through drug repurposing.
- To evaluate the efficacy of identified compounds and their synergistic potential in combination therapies.
Main Methods:
- Screening of 1,280 compounds from the Prestwick chemical library against three C. auris strains.
- Determination of Minimum Inhibitory Concentrations (MICs) using the EUCAST protocol for active compounds.
- Assessment of drug synergy using sub-inhibitory concentrations and Fractional Inhibitory Concentration Index (FICI).
Main Results:
- 27 compounds inhibited C. auris growth in initial screening; 7 demonstrated confirmed antifungal activity with MICs from 0.5 to 64 mg/L.
- Significant synergistic interactions were observed between suloctidil and voriconazole (FICI 0.11-0.5).
- Synergistic effects were also found between ebselen and anidulafungin (FICI 0.12-0.44).
Conclusions:
- Drug repurposing is a promising strategy for developing new treatments against Candida auris infections.
- Several FDA-approved drugs show potential as novel antifungal agents for C. auris.
- Combinations of existing drugs may enhance treatment efficacy and overcome resistance mechanisms.
More Related Videos
08:45Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
07:19A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms
Published on: October 21, 2010
Related Concept Videos
Emerging Adulthood
Fungal Group Zygomycota
Molecules and Compounds
Organic Compounds
Elements and Compounds
Elements
Elements are classified as atomic or molecular based on the nature of their basic units. They are unique forms of matter with specific chemical and physical properties that cannot break down into smaller substances by ordinary chemical reactions. There...
Introduction Cardiac Emergencies